Latest / Primary Care Perspectives

Primary Care Perspectives: Episode 154 - Nirsevimab (Beyfortus)
For the first time, a preventative medicine is available to protect infants and high-risk toddlers from respiratory syncytial virus (RSV). Lori Handy, MD, MSCE, attending physician in the Division of Infectious Diseases at Children's Hospital of Philadelphia, details the science behind the monoclonal antibody, nirsevimab (Beyfortus) and its importance, safety and efficacy, side effects, administration and proven benefits, such as a decrease in morbidity, as shown by clinical trials; and more. This podcast is for general informational and educational purposes only and is not to be considered…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.